Pre-Conference Day
Tuesday, October 8, 2024
8:00 am Check In & Registration
Workshop A
9:00 am Optimizing the Bioanalysis Strategy for ADCs – Developing Robust Bioanalytical Approaches for ADC Characterization
Synopsis
Join this workshop to gain insights into the latest bioanalytical strategies and techniques driving the development and evaluation of antibody-drug conjugates. Explore challenges and best practices in ADC characterization, quantification, and biomarker assessment, and learn how to translate bioanalytical findings into actionable insights for ADC clinical development.
• Utilizing cutting-edge analytical techniques to assess ADC structural integrity, drug-to-antibody ratio (DAR), and conjugation site occupancy
• Implementing in-vivo bioanalysis tools to better predict ADC behaviour
• Navigating challenges in ADC quantification and Pharmacokinetic assessment
• Addressing complexities in quantifying ADCs and their metabolites in biological matrices
• Strategies for overcoming matrix effects, stability challenges, and assay interference in ADC bioanalysis
• Interpreting bioanalytical data to guide ADC optimization, dosing regimen selection, and patient stratification strategies
• Leveraging biomarkers and pharmacodynamic endpoints to elucidate ADC mechanism of action and predict clinical outcomes
• Exploring innovative approaches for evaluating target engagement, payload release, and downstream signaling effects of ADCs
12:00 pm Networking Lunch Break
Workshop B
1:00 pm Navigating Dosing in ADC Combination Therapy – Optimizing Dosage Selection Strategies to Strike the Safety/Efficacy Balance
Synopsis
Join this workshop to gain comprehensive insights into optimizing dosing strategies for ADC combination therapies, and to unlock synergistic therapeutic outcomes whilst maintaining the safety/efficacy balance. Explore challenges, best practices, and future perspectives in designing, implementing, and translating different combination regimens into clinical practice for improved patient outcomes.
• Evaluating preclinical evidence and clinical data to identify synergistic combinations and optimal dosing regimens
• Assessing the impact of combination therapies on ADC pharmacokinetics, toxicity profiles, and therapeutic efficacy
• Optimizing dosing strategies for enhanced therapeutic outcomes
• Designing rational dosing regimens to maximize synergistic effects and minimize off-target toxicity in ADC combination therapies
• Leveraging pharmacokinetic and pharmacodynamic modeling to predict optimal dosing schedules and exposure levels
• Addressing translational challenges in predicting drug-drug interactions, pharmacokinetic/pharmacodynamic relationships, and optimal dose selection for ADC combination therapies
• Designing robust clinical trial protocols to evaluate safety, efficacy, and tolerability of combination regimens